Evidence map›Paper›PMID 34552583›Full record

ArticleFrontiers in immunology2021

Paradoxical Augmentation of Experimental Spondyloarthritis by RORC Inhibition in HLA-B27 Transgenic Rats.

Melissa N van Tok, Mohamed Mandour, Joseph Wahle, Mark E Labadia, Marleen G H van de Sande, Gerald Nabozny, Dominique L Baeten, Leonie M van Duivenvoorde

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Uncovering the Underworld of Axial Spondyloarthritis.International journal of molecular sciences · 2023
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Melissa N van TokDepartment of Clinical Immunology and Rheumatology, Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam University Medical Centers (UMC), Location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Mohamed MandourDepartment of Clinical Immunology and Rheumatology, Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam University Medical Centers (UMC), Location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Joseph WahleImmunology and Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
Mark E LabadiaImmunology and Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
Marleen G H van de SandeDepartment of Clinical Immunology and Rheumatology, Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam University Medical Centers (UMC), Location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Gerald NaboznyImmunology and Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
Dominique L BaetenDepartment of Clinical Immunology and Rheumatology, Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam University Medical Centers (UMC), Location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Leonie M van DuivenvoordeDepartment of Clinical Immunology and Rheumatology, Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam University Medical Centers (UMC), Location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Boehringer Ingelheim (United States) · USAcademic Medical Center · NLUniversity of Amsterdam · NLAmsterdam University Medical Centers · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: IL-17A plays a major role in the pathogenesis of spondyloarthritis (SpA). Here we assessed the impact of inhibition of RAR related orphan receptor-γ (RORC), the key transcription factor controlling IL-17 production, on experimental SpA in HLA-B27 transgenic (tg) rats. Methods: Experimental SpA was induced by immunization of HLA-B27 tg rats with heat-inactivated Results: Conclusion: Despite a significant suppression of the IL-17 axis, RORC inhibitor treatment accelerates and aggravates experimental SpA in the HLA-B27 tg rat model.

Indexed as

AnimalsDisease Models, AnimalFemaleHLA-B27 AntigenMaleNuclear Receptor Subfamily 1, Group F, Member 3RatsRats, Inbred LewRats, TransgenicSpondylarthritisHLA-B27 AntigenNuclear Receptor Subfamily 1, Group F, Member 3Rorc protein, ratHLA-B27 transgenic ratsIL-17AIL-22RORCspondyloarthritis

Identifiers

PMID34552583
PMCPMC8451327
OpenAlexW3196410499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.